Publication: Botulinum neurotoxins and botulism: A novel therapeutic approach
Issued Date
2011-05-01
Resource Type
ISSN
20726651
Other identifier(s)
2-s2.0-79958033240
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Toxins. Vol.3, No.5 (2011), 469-488
Suggested Citation
Jeeraphong Thanongsaksrikul, Wanpen Chaicumpa Botulinum neurotoxins and botulism: A novel therapeutic approach. Toxins. Vol.3, No.5 (2011), 469-488. doi:10.3390/toxins3050469 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/11926
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Botulinum neurotoxins and botulism: A novel therapeutic approach
Author(s)
Other Contributor(s)
Abstract
Specific treatment is not available for human botulism. Current remedial mainstay is the passive administration of polyclonal antibody to botulinum neurotoxin (BoNT) derived from heterologous species (immunized animal or mouse hybridoma) together with supportive and symptomatic management. The antibody works extracellularly, probably by blocking the binding of receptor binding (R) domain to the neuronal receptors; thus inhibiting cellular entry of the holo-BoNT. The antibody cannot neutralize the intracellular toxin. Moreover, a conventional antibody with relatively large molecular size (150 kDa) is not accessible to the enzymatic groove and, thus, cannot directly inhibit the BoNT zinc metalloprotease activity. Recently, a 15-20 kDa single domain antibody (VHH) that binds specifically to light chain of BoNT serotype A was produced from a humanized-camel VH/VHH phage display library. The VHH has high sequence homology ( > 80%) to the human VH and could block the enzymatic activity of the BoNT. Molecular docking revealed not only the interface binding between the VHH and the toxin but also an insertion of the VHH CDR3 into the toxin enzymatic pocket. It is envisaged that, by molecular linking the VHH to a cell penetrating peptide (CPP), the CPP-VHH fusion protein would be able to traverse the hydrophobic cell membrane into the cytoplasm and inhibit the intracellular BoNT. This presents a novel and safe immunotherapeutic strategy for botulism by using a cell penetrating, humanized-single domain antibody that inhibits the BoNT by means of a direct blockade of the groove of the menace enzyme. © 2011 by the authors; licensee MDPI, Basel, Switzerland.